Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study

Autor: Shari Damast, Molly Klein, Omar Najjar, Joan Tymon-Rosario, Britt K. Erickson, Alessandro D. Santin, Adriana Blakaj, Rebecca L. Stone, Michelle M Dolan, J. Stuart Ferriss, Ashley Cimino-Mathews, Maryam Shahi, Amanda N. Fader, Natalia Buza, Mahmoud A. Khalifa
Rok vydání: 2020
Předmět:
Zdroj: Gynecologic Oncology. 159:17-22
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2020.07.016
Popis: Background Human epidermal growth factor receptor 2 (HER2) has emerged as an important prognostic and therapeutic target in advanced stage and recurrent uterine serous carcinoma (USC). The significance of tumoral HER2 expression in early-stage disease has not been established. Methods This multi-center cohort study included women with stage I USC treated from 2000 to 2019. Demographic, treatment, recurrence, and survival data were collected. Immunohistochemistry (IHC) was performed for HER2 and scored 0–3+. Equivocal IHC results (2+) were further tested with fluorescence in-situ hybridization (FISH). HER2 positivity was defined as 3+ IHC or FISH positive. Results One hundred sixty-nine patients with stage I USC were tested for HER2; 26% were HER2-positive. There were no significant differences in age, race, stage, adjuvant therapy, or follow-up duration between the HER2-positive and negative cohorts. Presence of lymph-vascular space invasion was correlated with HER2-positive tumors (p = .003). After a median follow-up of 50 months, there were 43 (25.4%) recurrences. There were significantly more recurrences in the HER2-positive cohort (50.0% vs 16.8%, p Conclusions Given its significant association with worse recurrence and survival outcomes, HER2 positivity appears to be a prognostic biomarker in women with stage I uterine serous carcinoma. These data provide support for clinical trials with anti-HER2-directed therapy in early-stage disease.
Databáze: OpenAIRE
Externí odkaz: